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Abstract 
Background: Obstructive sleep apnea (OSA) is a common condition believed to be 
linked to cardiovascular comorbidities. Its potential effect on progression of subclinical 
atherosclerosis is not well studied. We tested the hypothesis that OSA is associated with 
progression of coronary artery calcium (CAC) score. We also evaluated whether 
traditional cardiovascular risk factors mediated the association.  
Methods: The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective 
epidemiologic cohort which has had a total of 5 clinic visits.  Our primary analytic 
sample included 2,603 participants who at or near visit 2 (2002-2004) completed a sleep 
questionnaire and underwent coronary computerized tomography (CT), and underwent a 
repeat coronary CT approximately 8 years later (Visit 5: 2010-2011).  Participants were 
categorized by their self-reported sleep breathing history: OSA: n= 102; Habitual snore: n 
= 666; Normal: n= 1835. mean age: 61.2). 
Results: Absolute CAC scores varied at visit 2, with the highest CAC prevalence among 
those with OSA, and lower but similar CAC prevalences among those who were habitual 
snorers or normal.  Over 8 years of follow-up, greater progression of CAC was observed 
among those with OSA vs. those classified as normal (mean increase of 227.7 vs.135.6 
Agatston units). This difference persisted after adjustment for BMI but was not 
significant after adjustment for cardiovascular risk factors (138.2 vs. 185.9 Agatston 
units; p = 0.08).  CAC progression among habitual snorers was similar to that observed in 
the normal group. 
  iv 
Conclusion: Self-reported sleep apnea was associated with CAC score progression after 
adjustment for demographics, behaviors and BMI. However, the association was not 
significant after accounting for cardiovascular risk factors which may mediate the 
association between OSA and CAC. 
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Background 
Obstructive sleep apnea (OSA) is a common condition, estimated to be prevalent in at 
least 3-7% of the adult population in developed countries.1 Beyond poor quality of sleep 
and its directly related symptoms, an emerging body of evidence links OSA to a more 
adverse cardiovascular risk factor profile and increased risk of cardiovascular disease 
(CVD) events.2,3  Individuals who snore are known to have a disproportionately higher 
prevalence of undiagnosed OSA than those who do not snore,4 and snoring has also been 
associated with higher risk of CVD risk factors and events.5-7    
In an effort to better understand the relation between OSA and CVD, examining the 
association between OSA and subclinical coronary atherosclerotic change may be 
valuable.8 Coronary artery calcium (CAC) assessed by coronary computerized 
tomography (CT) is a well-established surrogate marker that has been shown to be 
predictive of future coronary events in numerous studies.9,10  
Results have been inconsistent among the relatively few studies that have directly 
explored the association between OSA and CAC prevalence.11-15 To date, no studies have 
assessed the longitudinal association of OSA with change in CAC. In this study, we 
tested a hypothesis that over 8 years of follow-up participants with OSA would have a 
more pronounced increase in CAC, relative to participants who do not snore in a 
racially/ethnically diverse population free of overt CVD. We anticipated that participants 
who self-reported snoring would have an intermediate increase in CAC. The cross-
sectional association between self-reported OSA and CAC prevalence is also reported.   
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Methods 
Study population  
The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective cohort study of 
6,814 community-dwelling men and women aged 45–84 years without evidence of 
cardiovascular disease at baseline (2000-2002). Participants were recruited from 6 U.S. 
communities (Forsyth County, NC; Northern Manhattan and the Bronx, NY; Baltimore 
County, MD; St. Paul, MN; Chicago, IL; and Los Angeles County, CA) and self-
identified as White, Chinese, Black or Hispanic.16 A total of 6,232 participants attended 
MESA Exam 2 (September 2002- February 2004), of whom 5,395 completed the sleep 
history questionnaire.  Among those who completed the sleep questionnaire, 4,919 
underwent coronary CT at exam 2, or had coronary CT at both exam 1 (June 2000- 
August 2002) and 3 (March 2004 – September 2005), thereby allowing us to derive 
interpolated exam 2 CAC. These participants made up our “parent cohort”. We required 
that for the main analysis of CAC change, participants also attend MESA visit 5 coronary 
CT (April 2010- December 2011; attended by 55 % of the parent cohort). After excluding 
participants with a history of revascularization and one participant with apparent CAC 
measurement error, our final analytic sample included 2,603 participants (“final cohort”). 
The research protocols were approved by the Institutional Review Boards at each 
participating Institution and all participants gave written informed consent. Detailed 
descriptions of the study design and methods of MESA have been published previously. 
16 
Sleep Breathing History  
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A self-administered sleep history questionnaire conducted at exam 2 included the 
following 3 key questions regarding sleep breathing history: a) (Physician diagnosed 
sleep apnea question); Have you ever been told by a doctor that you had sleep apnea?  b) 
(Snoring question) Have you ever snored (now or at any time in the past)? ; c) (Snoring 
frequency question) How often do you snore now?  Figure 1 illustrates construction of 3 
sleep breathing group (OSA, Habitual snoring, Normal) based on the response to these 
questions.  Since OSA (vs. central sleep apnea) is by far the most common form of sleep 
apnea in the absence of heart failure or stroke, we considered self-reported physician 
diagnosed sleep apnea to be OSA in this study. In addition, information on subjective 
perception of excessive daytime sleepiness was extracted from the question: How often 
do you feel excessively (overly) sleepy during the day?  This information was used to test 
for potential effect modification. Participants who responded “never /rarely” (1 day/ 
month or less) or “sometimes” (2-4 days/month) were considered not to have excessive 
daytime sleepiness.  Those who responded “often” (5-15 days/month) or “almost always” 
(16-30 days/ month) were considered to have excessive daytime sleepiness.   
 
Coronary artery calcium 
Details of the technique and methodology of the scans and approach to quantifying CAC 
have been previously published.17.  Briefly, CAC imaging was conducted using either 
electron-beam (EBT; Imatron C-150; Imatron, San Francisco, California) or 
multidetector CT (MDCT; Lightspeed, General Electric Medical System, Waukesha, 
Wisconsin; or Volume Zoom, Siemens, Erlanger, Germany). CT images were acquired 
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by a certified technologist and read by a trained physician-reader at a centralized reading 
center (Los Angeles Biomedical Research Institute, Torrance, California).  CAC scores 
were quantified by the Agatston method18 from two consecutively obtained CT scans at 
each visit and average CAC scores were obtained. CAC scores were subsequently 
adjusted with a standard calcium phantom that was scanned along with the participant.17 
Excellent inter- and intra-observer agreement were found based on the kappa statistics 
(k = 0.93 and 0.90, respectively).19  
The absolute difference in CAC score between MESA exam 2 and exam 5 was used as 
our primary endpoint, representing change in CAC over an average of 8 years. By design, 
only 50% of the MESA sample underwent CT at Exam 2. For those who did not undergo 
CT at exam 2, interpolated CAC was derived by averaging CAC of exam 1 and 3 
assuming linear rate of change in CAC. Since approximately half of the participants who 
underwent exam 1 CT were randomly allocated to have a follow up CT at either exam 2 
or 3 but not both, there was no overlap between the cohorts who underwent CT at exam 2 
and 3.  Notably, only one quarter of the full MESA cohort underwent CAC scans at exam 
4 (September 2005 – May 2007); to maximize the size of cohort and the time interval 
over which CAC progression might occur, exam 5 CAC was chosen for calculating CAC 
change instead of exam 4 CAC.   
Covariates 
Information on demographics, smoking, physical activity, and medical conditions were 
obtained by questionnaire at exam 2. Smoking status was categorized as never, former, or 
current smoker. Physical activity was determined by calculation of weekly meter-minute 
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of total walking, conditioning and sports activity. Body mass index (BMI) obtained at 
exam 2 were categorized into normal (BMI <25 kg/m2), overweight (25≤ BMI <30 
kg/m2) and obese (BMI ≥ 30 kg/m2). Use of diabetes, hypertension and cholesterol 
medications was determined by questionnaire, and from medication containers which 
were brought to the exam 2 clinic visit. Blood samples collected after a 12 h fast were 
used to determine fasting glucose level, low (LDL) and high density lipoprotein-(HDL) 
cholesterol. Diabetes was defined as a fasting glucose ≥7.0 mmol/l (126 mg/dl), or use of 
insulin or oral hypoglycemic medications. Hypertension was determined by the sixth 
report of the Joint National Committee (1997) criteria.  
Statistical analysis 
Characteristics of participants were compared based on the self-reported sleep breathing 
history, the main exposure predictor of interest (i.e. No snoring, Snoring and OSA), using 
chi-square test or one way analysis of variance for categorical and continuous variables, 
respectively. Mean (standard deviation; SD) and percentage were used to describe 
continuous and categorical variables, as appropriate.  
Absolute CAC score and prevalence for CAC (CAC score >0, i.e. presence of CAC) and 
CAC 400 (CAC score> 400, i.e. high burden of CAC) in the final cohort at baseline were 
calculated according to sleep breathing history characteristics using Kruskal Wallis test 
(with pair-wise post-hoc Wilcoxon test) and chi-square test respectively.  
For multivariate comparison of the prevalence rate, Log binomial regression with a 
Poisson distribution was employed, with adjustment using the following nested models. 
Model 1:  age, gender race/ethnicity, education level, site, smoking and physical activity; 
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Model 2: Model 1 + BMI category; Model 3: Model 2 + several potential mediators of 
the association between OSA and CAC change (i.e. prevalent diabetes, prevalent 
hypertension, antihypertensive medication, HDL-C, LDL-C and lipid lowering 
medication).   
The main outcome of interest, absolute CAC change was determined by subtracting CAC 
score at exam 2 (measured or interpolated) from that at exam 5. Multiple linear 
regression was performed to calculate the mean CAC change (and 95% confidence 
intervals) between the sleep breathing groups. The same models were employed as for the 
baseline prevalence comparison. Since there are several different approaches to analyzing 
change20 , as a sensitivity analysis we modeled change with absolute CAC at exam 5 as 
the dependent variable, without considering baseline CAC values. Possible effect 
modification of associations between sleep breathing pattern and CAC change by age, 
gender, race, BMI category and reported excessive daytime sleepiness were tested by 
including cross-product terms in the models. A p-value less than 0.05 was considered 
significant. Sensitivity analysis was also performed after censoring participants with 
negative CAC change, which may represent measurement error. All statistical analyses 
were performed using SAS version 9.3 (SAS Institute, Cary, N.C.).  
 
Results 
A total of 2,603 participants were eligible for the main analysis evaluating change in 
CAC score between exam 2 and 5. This final cohort included 102 (3.9%) participants 
with OSA, 666 (25.6 %) with habitual snoring, and 1835 (70.5 %) without a history of 
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habitual snoring or OSA, who were therefore considered ‘normal’. This distribution was 
similar to the parent cohort [n=4,919, OSA: n = 3464 (3.9 %), Habitual snoring: n = 1261 
(25.6 %), Normal: n = 194 (70.4 %)]. The baseline characteristics are shown in Table 1. 
Participants with OSA, when compared to those without OSA, were more likely to be 
male, obese and characterized by a higher prevalence of current smoking, diabetes, 
hypertension and being on medication for hypertension and hyperlipidemia. Levels of 
both HDL and LDL were lower among the OSA group; however after restricting the 
analysis to participants not taking lipid lowering medications, LDL levels were similar 
across sleep breathing categories. Overall, characteristics of the habitual snoring group 
were similar to those of the normal group. More than a third of participants with OSA 
(38.6%) reported having excessive daytime sleepiness compared to 27.9% and 18.5% in 
the habitual snoring and normal groups, respectively (p < 0.0001). Unadjusted baseline 
CAC score and CAC prevalence were significantly different across the groups (Table 1).  
 
1. Prevalence of CAC at baseline from parent cohort (n =4919) 
At baseline, the overall prevalence of positive CAC (CAC> 0) was high in all groups, but 
was highest in the OSA group (OSA: 64.4%; Habitual snoring: 55.0%; Normal: 55.6%, p 
= 0.04). Prevalence of high CAC burden (CAC> 400) showed similar pattern (OSA: 
19.1%, Habitual snore: 10.4%, Normal: 12.0%, p = 0.002). In multivariate analyses, for 
CAC>0 the association was no longer present when adjusted for BMI (Table 2a). For 
CAC>400 the association persisted after adjustment for BMI and CVD risk factors (Table 
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2b).  For both CAC>0 and CAC>400, the habitual snoring group behaved similarly to the 
normal group.     
 
2. Longitudinal change in CAC (n = 2603) 
Over 8 years of follow-up, CAC change in the final cohort ranged from -362 to 3261 and 
its mean and median were 140.4 and 25.9, respectively. Unadjusted change in CAC was 
significantly more pronounced in the OSA group compared to normal or habitual snoring 
groups [OSA: 227.7 (95% CI: 173.3-282.1); Habitual snoring: 140.4 (95% CI: 119.1-
161.6), Normal: 135.6 (95% CI: 122.8-148.4)]. The pattern persisted in multivariate 
analysis adjusting for baseline demographic, life style factors [Model 1, OSA: 220.6 
(95% CI: 169.2-272.0); Habitual snoring: 138.9 (95% CI: 118.5-159.3), Normal: 132.3 
(95% CI: 120.1-144.4)] and BMI [Model 2, OSA: 204.2 (95% CI: 152.8-255.5); Habitual 
snoring: 132.6 (95% CI: 112.2-153.0), Normal: 135.5 (95% CI: 123.3-147.6)]. Figure 2 
shows CAC scores at visit 2 and at visit 5, stratified by sleep breathing category, with 
model 2 adjustments. With further adjustment for CVD risk factors (model 3) the 
association between OSA and the normal group became statistically insignificant (p = 
0.08), while the association remained significant in the between OSA and the habitual 
snoring group (p = 0.04). In sensitivity analyses modeling CAC at exam 5 (the follow up 
CAC) without taking into account baseline CAC, the results were slightly attenuated 
(Supplemental table 1).   
Effect modification was not present by age, gender, BMI category or excessive daytime 
sleepiness but was present by race. Subsequent stratified analysis showed that in blacks, 
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no difference in CAC change was observed across the groups. This result should be 
viewed cautiously, however, given the number of comparisons and the limited sample 
size for race specific analyses.   
In alternative analyses, when the OSA group was compared to combined ‘no OSA group’ 
(Habitual snoring + Normal group), the difference remained significant in model 1-2 but 
became marginally insignificant in model 3 adjusting for CVD risk factors (p =0.06) 
(Supplemental table 2). Since negative change in CAC might be due to measurement 
error rather than a true regression, we performed analysis by excluding subjects (6%) 
with any negative change. The results were similar before and after the exclusion (data 
not shown). Finally because CAC change did not exhibit normally distributed pattern 
owing to large portion of cohort without significant change, we also performed the 
analysis using log-transformed CAC change. However results were largely unchanged 
(data not shown).   
 
Discussion 
In this large racially and ethnically diverse cohort without evidence of CVD at baseline, 
we found that having OSA based on self-reported physician diagnosis versus being a 
habitual snorer or reporting a normal sleep breathing pattern was associated with a 
significantly greater progression of CAC, as measured by absolute change in CAC scores 
over an average of 8 years. These associations remained significant even after adjusting 
for BMI, but were modestly attenuated after additionally accounting for key CVD risk 
factors, such as hypertension, diabetes and hyperlipidemia, which may be mediators of 
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the association between OSA and CAC progression. OSA has been linked to the 
development of these cardiovascular risk factors,21,22 and these risk factors have been 
associated with CAC incidence and progression.23  
Relatively few cross-sectional studies have explored the association between OSA and 
CAC prevalence, and they have yielded conflicting results, in both clinical and 
population based settings. One clinic based study of patients who were referred for both a 
sleep study and coronary CT showed a significantly higher prevalence of positive CAC 
and a higher CAC score in patients with OSA in a dose dependent manner according to 
the severity.14 Such a finding however was not replicated in a similarly designed clinic 
based study.13  One population based study showed an independent linear association of 
OSA severity with CAC score in women of all ages and in men less than 65 years old.12 
To the contrary, other studies involving a community cohort failed to show a significant 
independent association between OSA and prevalence or burden of CAC after adjusting 
for BMI.11,15 Likewise, in the present study, the association between OSA and presence 
of CAC at baseline was not significant after adjusting for BMI. When CAC above 400 
was considered, the association did persist after accounting for BMI, as well as traditional 
CVD risk factors.  
A major advantage of our analysis over prior work is the prospective design, assessing 
the relation of OSA and CAC change over 8 years of follow-up. While baseline CAC 
score offers independent incremental information over and above traditional risk factors 
in the prediction of all-cause mortality,24 progression of CAC has been shown to further 
increase the risk for coronary heart disease events in the MESA cohort.25 Also within 
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MESA, self-reported OSA was found to be predictive of increased risk of incident CVD 
events and all-cause mortality.26 Since OSA is considered a treatable condition, this 
provides an important basis for future studies evaluating the treatment of OSA on the 
development and progression of cardiovascular risk factors which may mediate the 
association between OSA and CAC progression.  
Given that people who habitually snore are more likely to have undiagnosed OSA,4 and 
the body of evidence relating habitual snoring to subclinical atherosclerosis and 
cardiovascular morbidities,5-7 we hypothesized that those reporting ‘habitual snoring’ 
would have greater CAC progression than those reporting a normal sleep breathing 
pattern. However our analysis showed that, overall, CAC progression in the habitual 
snoring group was similar to that of the normal group. While this result suggests no 
significant association of habitual snoring with CAC progression, it may have been partly 
attributed to lack of validity of self-reported snoring history by participants possibly 
coupled with limitations of the survey to effectively separate the true “habitual” snorers 
from non-habitual snorers.27 Thus, in future studies it would be valuable to explore CAC 
progression using an objective measurement of snoring (e.g. Audiotape recording or 
standard sleep study). 
Although the underlying mechanism of OSA’s effect on CAC progression is uncertain, it 
likely acts through repetitive airway obstruction and hypoxemia  resulting in endothelial 
dysfunction28 and inflammation29,30 via oxidative stress31 or heightened sympathetic 
activity32. Through these mechanisms, OSA may exert its deleterious effect on the 
progression of subclinical atherosclerosis either directly or indirectly via mediators such 
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as hypertension33, diabetes34 and metabolic syndrome,35 which can all lead to hard CVD 
events such as coronary heart disease, stroke and heart failure as shown in recent 
prospective studies.3,36 
Key strengths of this study are the prospective design which included an average of 8 
years of follow-up, objectively measured CAC, and diverse study sample. A limitation of 
our study is the relatively small number of participants with OSA, which at times resulted 
in wide confidence intervals and perhaps imprecise estimates. OSA is known to be highly 
underdiagnosed in the community, particularly as many individuals with OSA lack 
classical symptoms.37  Since in our sample diagnosis of OSA relied solely on self-
reported history but not on the objective measurement, the prevalence of OSA (4%) 
reported in our study is almost certainly an underestimate. The subsequent 
misclassification would have likely biased our results toward the null. Bias related to 
unmeasured confounders in our hypothesized casual model or residual confounding 
resulting from inaccurate information of covariates should be also considered. In addition 
it is possible that a number of participants in the OSA group may have been receiving 
treatment for OSA, which may have weakened the association, though to date there is no 
supporting evidence of a beneficial effect of therapy on the progression of CAC. 
However, a graded relationship has been noted between adherence to OSA treatment 
using continuous positive airway pressure and total mortality.38  Conversely, one can 
assume that participants with OSA in our study represent more symptomatic individuals 
who have more severe OSA, as they underwent a sleep study and received a diagnosis of 
OSA. 
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In addition, several caveats need to be explained in regards to the methodology of 
quantifying and analyzing CAC progression in our study. First we observed negative 
CAC change in varying degrees in a small number of subjects (6% of the final cohort). 
This likely represents measurement error, though true regression of coronary calcification 
is not impossible. Analysis removing participants with negative CAC progression did not 
change the results. Second, the absolute CAC score used to measure progression in our 
study can introduce an overestimation of the actual progression of CAC in subjects with 
higher baseline CAC as compared with those with low baseline CAC due to higher 
interscan variability.39 Accordingly, given higher baseline CAC burden found in OSA 
group, we repeated the analysis adjusting for the baseline CAC score. The overall results 
were similar. Third, to enhance power, interpolated data based on an assumption of linear 
progression was used to estimate baseline CAC in approximately half of the cohort (those 
who had CAC measurement at Exams 1 and 3, but not Exam 2). Since our focus was on 
the absolute CAC change rather than an incidence of CAC, we believe interpolation was 
an acceptable approach.  
 
In summary, in this large and racially/ethnically diverse cohort participants who self-
reported physician diagnosis of OSA experienced greater CAC progression over 8 years 
of follow-up, relative to those who were habitual snorers or reported a normal sleep 
breathing pattern. Attenuation of the association after adjusting for important CVD risk 
factors suggests that these factors may mediate the association between OSA and CAC 
progression. CAC progression was similar among participants who reported habitual 
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snoring and those classified as normal. Our finding that participants with OSA 
experienced greater CAC progression provides an important rationale for further studies 
focusing on the effect of objectively measured OSA on the development of 
cardiovascular risk factors and subclinical cardiovascular disease.   
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[Tables] 
 
Table 1.  Characteristics of the participants in final cohort by self-reported sleep 
breathing history (n = 2603): MESA.  
Variables Normal (n = 1835) Habitual Snoring (n= 666) OSA  (n=102) p value 
Demographics         
Age (years), mean (SD) [range] 61.8a  (9.4)   [46-86] 59.6b (8.6) [46-83] 59.5b (8.6) [46-81] <.0001 
Male n (%) 796 (43.4) 401 (60.2) 76 (74.5) <.0001 
Race n (%) 
   
0.002 
  White, Caucasian 739 (40.3) 234 (35.1) 48 (47.1) 
   Chinese American 203 (11.1)  97 (14.6) 7 (6.9) 
   Black, African-American 504 (27.5) 162 (24.3) 30 (29.4) 
   Hispanic 389 (21.2) 173 (26.0) 17 (16.7) 
 Education, n (%) 
   
0.0499 
< High school degree 226 ( 12.3 ) 100 (15.0) 6 (5.9) 
    High school degree or some college 883 (48.2) 300 (45.1) 47 (46.1) 
   College graduate 725 (39.5) 265 (39.9) 49 (48.0) 
 Income, n (%) 
   
0.003 
 < $20000 328 (18.5) 112 (17.3) 8 (8.0) 
 $20000 – 50000 679 (38.3) 233 (36.0) 30 (30.0) 
 > $50000 767 (43.2) 302 (46.7) 62 (62.0)   
Life style  
    Smoking n (%) 
   
0.09 
Never 889 (48.7) 288 (43.7) 39 (38.6) 
 Former 754 (41.3) 295 (44.8) 49 (48.5) 
 Current 184 (10.1) 76 (11.5) 13 (12.9)   
Physiologic Characteristics 
    BMI category (kg/m2), n (%)  
   
<.0001 
< 25 530 (28.9) 137 (20.6) 9 (8.8) 
 25 – 30 775 (42.3) 254 (38.1) 36 (35.3) 
 ≥ 30 529 (28.8) 275 (41.3) 57 (55.9)   
  16 
 
 
 
 
 
 
 
 
 
CA
C: 
coronary artery calcium; OSA: obstructive sleep apnea. For continuous variables, values without sharing 
common alphabet letters denote significant difference. * Kruskal Wallis test with pair-wise post-hoc 
Wilcoxon test was used.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comorbidities  
    Prevalent diabetes, n (%) 209 (11.5) 101 (15.3) 21 (20.8) 0.002 
Prevalent HTN, n (%) 737 (40.6) 285 (43.3) 48 (47.5) 0.2 
Hypertension medication, n (%) 655 (37.3) 270 (42.7) 47 (47.5) 0.01 
HDL cholesterol (mg/dL) mean  (SD) [range] 52.9a (15.2) [21-161] 48.0b (12.4) [24-111] 46.8b (10.5) [24-77] <.0001 
LDL cholesterol (mg/dL)  mean (SD) [range] 113.0a (31.0) [21-243] 117.0b (30.3) [41-281] 104.3c (30.1) [34-178] <.0001 
Lipid Lowering meds, n (%) 380 (21.7) 75 (20.9) 31 (31.3) 0.07 
Baseline CAC     
CAC score mean* (median) [range]   108.5a (0) [0-4744.1] 108.6a (1.2) [0-2963.9] 163.2b (19.3) [0-1175.5] 0.0006 
Prevalence CAC > 0, n (%) 900 (49.1) 347 (52.1) 66 (64.7) 0.005 
Prevalence CAC > 400, n (%) 132 (7.2) 48 (7.2) 17 (16.7) 0.002 
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Table 2. Prevalence ratio of positive CAC (Table 3a: CAC>0, Table 3b: CAC>400) at 
baseline in parent cohort by sleep breathing history (n=4919): MESA .  
 
2a (CAC>0) 
 Habitual snoring vs. Normal OSA vs. Habitual snoring OSA vs. Normal 
 PR 95% CI p value PR 95% CI p value PR 95% CI p value 
Model 1 1.05 0.99-1.11 0.1 1.11 1.00-1.23 0.05 1.16 1.06-1.29 0.002 
Model 2 1.02 0.96-1.08 0.6 1.07 0.96-1.19 0.2 1.08 0.98-1.20 0.1 
Model 3 1.03 0.97-1.08 0.4 1.03 0.92-1.15 0.7 1.05 0.95-1.17 0.4 
 
2b (CAC> 400) 
 Habitual snoring vs. Normal OSA vs. Habitual snoring OSA vs. Normal 
 PR 95% CI p value PR 95% CI p value PR 95% CI p value 
Model 1 1.09 0.90-1.31 0.4 1.51 1.11-2.06 0.009 1.64 1.24-2.17 0.0005 
Model 2 1.02 0.84-1.24 0.8 1.38 1.01-1.88 0.04 1.41 1.06-1.87 0.02 
Model 3 1.05 0.87-1.27 0.6 1.30 0.95-1.77 0.1 1.36 1.02-1.80 0.03 
 
Model 1 adjusted for age, race, gender, site, income level, educational level, smoking status and physical 
activity level (n = 4703). Model 2 adjusted for Model 2 + BMI category (4702). Model 3 adjusted for 
Model 2 + Diabetes, Hypertension, Hypertension medication, LDL, HDL and Cholesterol medication 
(4401). CAC: coronary artery calcium; OSA: obstructive sleep apnea; PR: prevalence ratio. 
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Table 3. Comparison of absolute CAC score change over 8 years of follow-up by sleep 
breathing history in the final analytic cohort (n= 2603): MESA.  
 
 
 Normal 
(n = 1835) 
Habitual  snoring 
(n= 666) 
OSA 
(n=102) 
Habitual snoring  
vs. Normal 
OSA 
vs. Habitual 
snoring 
OSA 
vs. Normal 
 Mean 95% CI Mean 95% CI Mean 95% CI P value 
Model 1 132.3 120.1-144.4 138.9 118.5-
159.3 
220.6 169.2-272.0 0.6 0.004 0.001 
Model 2 135.5 123.3-147.6 132.6 112.2-
153.0 
204.2 152.8-255.5 0.8 0.01 0.01 
Model 3 138.2 126.2-150.3 129.7 109.3-
150.2 
185.9 134.8-236.9 0.5 0.04 0.08 
 
Model 1 adjusted for age, race, gender, site, income level, educational, smoking status and physical activity 
level (n = 2502). Model 2 adjusted for Model 1 + BMI category (n= 2501). Model 3 adjusted for Model 2 + 
Diabetes, Hypertension, Hypertension medication, LDL, HDL and Cholesterol medication (n= 2344). 
CAC: coronary artery calcium, OSA: obstructive sleep apnea. 
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[Figures] 
 
Figure 1. Construction of three sleep breathing history groups based on the self-
administered sleep history questionnaire in final cohort (n = 2603): MESA 
 
 
Snoring frequency response definitions: Sometimes:  snoring up to 2 nights a week; Frequently: snoring 3-5 
nights a week; Always or almost always: snoring 6-7 nights a week. Participants who responded either 
“No” or “don’t know” to the question (a) but responded “Yes” to the snoring question (b) and “don’t 
know” to the snoring frequency question (c) were also classified as normal.  OSA: obstructive sleep apnea. 
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Figure 2.  Adjusted* absolute CAC scores and CAC progression over 8 year period 
stratified by sleep breathing history: MESA  
 
 
Mean and 95% CI of CAC score at exam 2 and 5 by sleep breathing history. *Model 2 adjusted for age, 
race, gender, site, income level, educational, smoking status, physical activity level and BMI category (n= 
2501).  P values comparing CAC change between the groups. Model 2: OSA vs. Normal: 0.01; OSA vs. 
Habitual snoring: 0.01; Habitual snoring vs. Normal: 0.8. CAC: coronary artery calcium, OSA: obstructive 
sleep apnea 
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[Supplemental Tables] 
 
 
Supplemental Table 1. Absolute CAC score at exam 5 without accounting for baseline 
CAC values by self-reported sleep breathing category: MESA (Using final cohort; n = 
2603) 
 
 Normal 
(n = 1835) 
Habitual  snoring 
(n= 666) 
OSA 
(n=102) 
Habitual 
snoring  
vs. Normal 
OSA 
vs. Habitual 
snoring 
OSA 
vs. Normal 
 Mean 95% CI Mean 95% CI Mean 95% CI P value 
Model 1 238.5 214.9-262.1 251.7 212.2-291.3 365.6 265.9-465.3 0.6 0.04 0.02 
Model 2 242.5 218.9-266.1 243.9 204.2-283.5 345.5 245.5-445.5 1.0 0.06 0.051 
Model 3 249.6 225.5-273.7 243.3 202.4-284.2 311.9 209.7-414.1 0.8 0.8 0.2 
 
Model 1 adjusted for age, race, gender, site, income level, educational, smoking status and physical activity 
level (n = 2502). Model 2 adjusted for Model 1 + BMI category (n= 2501). Model 3 adjusted for Model 2 + 
Diabetes, Hypertension, Hypertension medication, LDL, HDL and Cholesterol medication (n= 2344). 
CAC: coronary artery calcium, OSA: obstructive sleep apnea. 
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Supplemental Table 2. Comparison of absolute CAC score change based on the presence 
of OSA in final cohort (n= 2603): MESA. 
 
 No OSA OSA  
 n = 2501 n = 102  
 Mean CI Mean CI p value 
Model 1 134.0 123.7-144.4 220.3 169.0-271.7 0.001 
Model 2 134.7 124.4-145.0 204.3 153.0-255.7 0.009 
Model 3 136.0 125.8-146.2 186.4 135.4-237.4 0.06 
 
Model 1 adjusted for age, race, gender, site, income level, educational, smoking status and physical activity 
level (n = 2502). Model 2 adjusted for Model 1 + BMI category (n= 2501). Model 3 adjusted for Model 2 + 
Diabetes, Hypertension, Hypertension medication, LDL, HDL and Cholesterol medication (n= 2344). 
CAC: coronary artery calcium, OSA: obstructive sleep apnea. 
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